Dengue vaccine candidates in development
- PMID: 19802583
- DOI: 10.1007/978-3-642-02215-9_10
Dengue vaccine candidates in development
Abstract
Each of the DENV serotypes can cause the full spectrum of dengue illness. Epidemiological studies have implicated preexisting heterotypic DENV antibody as a risk factor for more severe disease upon secondary DENV infection. For these reasons, a successful DENV vaccine must protect against all four DENV serotypes. Live attenuated DENV vaccine candidates are the furthest along in development and clinical evaluation. Two live attenuated tetravalent vaccine candidates are in Phase 2 clinical trials in DENV endemic regions. Numerous other vaccine candidates including inactivated whole virus, recombinant subunit protein, DNA and virus-vectored vaccines are also under development. Those DENV vaccine candidates that have been evaluated in preclinical animal models or in clinical trials will be discussed.
Similar articles
-
A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.Expert Rev Vaccines. 2016;15(4):497-508. doi: 10.1586/14760584.2016.1128328. Epub 2016 Feb 22. Expert Rev Vaccines. 2016. PMID: 26635182 Review.
-
Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.Virology. 2010 Jan 20;396(2):280-8. doi: 10.1016/j.virol.2009.10.023. Epub 2009 Nov 13. Virology. 2010. PMID: 19913867
-
The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.Asian Pac J Allergy Immunol. 2015 Sep;33(3):182-8. doi: 10.12932/AP0508.33.3.2015. Asian Pac J Allergy Immunol. 2015. PMID: 26342114
-
DENGUE VACCINES.Southeast Asian J Trop Med Public Health. 2015;46 Suppl 1:138-45. Southeast Asian J Trop Med Public Health. 2015. PMID: 26506740
-
Dengue virus vaccine development.Adv Virus Res. 2014;88:315-72. doi: 10.1016/B978-0-12-800098-4.00007-6. Adv Virus Res. 2014. PMID: 24373316 Review.
Cited by
-
A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein.PLoS One. 2012;7(4):e33451. doi: 10.1371/journal.pone.0033451. Epub 2012 Apr 3. PLoS One. 2012. PMID: 22509258 Free PMC article.
-
Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis.BMC Infect Dis. 2012 Sep 28;12:233. doi: 10.1186/1471-2334-12-233. BMC Infect Dis. 2012. PMID: 23020074 Free PMC article. Review.
-
Genetics and morphology of Aedes aegypti (Diptera: Culicidae) in septic tanks in Puerto Rico.J Med Entomol. 2011 Nov;48(6):1095-102. doi: 10.1603/me11129. J Med Entomol. 2011. PMID: 22238867 Free PMC article.
-
Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.Hum Vaccin Immunother. 2013 Nov;9(11):2317-25. doi: 10.4161/hv.25562. Epub 2013 Jul 9. Hum Vaccin Immunother. 2013. PMID: 23839107 Free PMC article. Clinical Trial.
-
Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis.BMJ Open. 2019 Mar 13;9(3):e019368. doi: 10.1136/bmjopen-2017-019368. BMJ Open. 2019. PMID: 30872537 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
